Lead Product(s): TAK-831
Therapeutic Area: Psychiatry/Psychology Product Name: TAK-831
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Neurocrine Biosciences
Deal Size: $2,015.0 million Upfront Cash: $120.0 million
Deal Type: Licensing Agreement June 16, 2020
Under the terms of the agreement, Takeda granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including three clinical stage assets for schizophrenia, treatment-resistant depression and anhedonia.